ProfileGDS4814 / ILMN_1663425
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 49% 20% 29% 47% 39% 45% 50% 35% 26% 41% 29% 38% 59% 36% 47% 39% 58% 50% 20% 47% 38% 25% 46% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)50.063149
GSM780708Untreated after 4 days (C2_1)43.611120
GSM780709Untreated after 4 days (C3_1)45.347929
GSM780719Untreated after 4 days (C1_2)49.595347
GSM780720Untreated after 4 days (C2_2)47.541939
GSM780721Untreated after 4 days (C3_2)48.923845
GSM780710Trastuzumab treated after 4 days (T1_1)50.370350
GSM780711Trastuzumab treated after 4 days (T2_1)46.637735
GSM780712Trastuzumab treated after 4 days (T3_1)44.823526
GSM780722Trastuzumab treated after 4 days (T1_2)48.038241
GSM780723Trastuzumab treated after 4 days (T2_2)45.308129
GSM780724Trastuzumab treated after 4 days (T3_2)47.256938
GSM780713Pertuzumab treated after 4 days (P1_1)54.916859
GSM780714Pertuzumab treated after 4 days (P2_1)46.784336
GSM780715Pertuzumab treated after 4 days (P3_1)49.686747
GSM780725Pertuzumab treated after 4 days (P1_2)47.481439
GSM780726Pertuzumab treated after 4 days (P2_2)54.257258
GSM780727Pertuzumab treated after 4 days (P3_2)50.58150
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)43.598220
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)49.469147
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)47.177738
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)44.676525
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)49.281846